




PHARMACEUTICAL 2021

ADIAL PHARMACEUTICALS INC.
Rank 336 of 402





PHARMACEUTICAL 2021

ADIAL PHARMACEUTICALS INC. Rank 336 of 402

The relative strengths and weaknesses of ADIAL PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ADIAL PHARMACEUTICALS INC. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 23% points. The greatest weakness of ADIAL PHARMACEUTICALS INC. is the variable Net Income, reducing the Economic Capital Ratio by 205% points.

The company's Economic Capital Ratio, given in the ranking table, is -115%, being 163% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	5,136
Cost of Goods Sold	0
Intangible Assets	5.6
Liabilities, Current	1,505
Liabilities, Non-Current	0
Other Assets	350
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	35
Other Revenues	0
Property and Equipment	0
Research and Development	5,853
Selling, General and Administrative Expense	5,075

Output Variable	Value in 1000 USD
Assets	5,491
Liabilities	1,505
Expenses	10,928
Revenues	0
Stockholders Equity	3,986
Net Income	-10,893
Comprehensive Net Income	-10,893
Economic Capital Ratio	-115%